Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transmembrane protein 223 (TMEM223) is a conserved, integral membrane protein localized to the mitochondrial inner membrane, with its N- and C-termini exposed to the matrix. It is a member of the TMEM70/TMEM186/TMEM223 protein family and functions as a mitochondrial ribosome-associated factor essential for the early steps of cytochrome c oxidase (complex IV) assembly. TMEM223 stimulates the translation of mitochondrial-encoded COX1 mRNA and is a constituent of early COX1 assembly intermediates. Loss of TMEM223 in human cells impairs cytochrome c oxidase activity by reducing COX1 synthesis but does not entirely abolish complex IV assembly, suggesting partial redundancy with other assembly factors. TMEM223 is not known to act as a classical therapeutic target (receptor, transporter, enzyme), and there are no reported direct drug interactions or clinical biomarker applications.
Not applicable (no drugs target this protein directly; it acts as a biogenesis/assembly factor for complex IV of mitochondrial OXPHOS)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transmembrane protein 223 (TMEM223).